Pfizer/BioNTech say Covid-19 vaccine likely to prevent asymptomatic infection

According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from Covid-19 than those who had received the vaccine.

Pfizer Inc and BioNTech SE said on Wednesday that real-world data from Israel suggests that their Covid-19 vaccine is 94% effective in preventing asymptomatic infections, meaning the vaccine could significantly reduce transmission.

The data, collected between Jan. 17 and March 6, has not yet been peer reviewed. (ANI Photo)

The companies also said the latest analysis of the Israeli data shows the vaccine was 97% effective in preventing symptomatic disease, severe disease and death. That is basically in line with the 95% efficacy Pfizer and BioNTech reported from the vaccine's late-stage clinical trial in December.

According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from Covid-19 than those who had received the vaccine.

The data, collected between Jan. 17 and March 6, has not yet been peer reviewed.